HOHL BENJAMIN (CHIEF FINANCIAL OFFICER) sold 11.6% of their position (6.02K shares) of ENLIVEN THERAPEUTICS, INC. on the open market
Open‑market sale worth $316.8K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
Common Stock
Shares
+1.07K
Price / share
$2.48
Trade value
$2.66K
% of position
Common Stock
Shares
−324.00
Price / share
$49.97
Trade value
$16.19K
% of position
Common Stock
Shares
−369.00
Price / share
$51.48
Trade value
$19K
% of position
Common Stock
Shares
−2.56K
Price / share
$52.32
Trade value
$134.14K
% of position
Common Stock
Shares
−2.64K
Price / share
$53.38
Trade value
$140.82K
% of position
Common Stock
Shares
−123.00
Price / share
$53.87
Trade value
$6.63K
% of position
Net shares
−4.95K
Net value
-$314.12K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 7/17/2026 | M · Option Exercise | +1.07K | $2.48 | $2.66K | 2.1% | 51K | 52.07K |
| Common Stock Direct | 7/17/2026 | S · Sale | −324.00 | $49.97 | $16.19K | 0.6% | 52.07K | 51.75K |
| Common Stock Direct | 7/17/2026 | S · Sale | −369.00 | $51.48 | $19K | 0.7% | 51.75K | 51.38K |
| Common Stock Direct | 7/17/2026 | S · Sale | −2.56K | $52.32 | $134.14K | 5.0% | 51.38K | 48.81K |
| Common Stock Direct | 7/17/2026 | S · Sale | −2.64K | $53.38 | $140.82K | 5.4% | 48.81K | 46.18K |
| Common Stock Direct | 7/17/2026 | S · Sale | −123.00 | $53.87 | $6.63K | 0.3% | 46.18K | 46.05K |
| Total | −4.95K | -$314.12K | ||||||
Stock Option (right to buy)
Common Stock
1.07K shares
Shares
−1.07K
Strike price
2.48
Held after
84.97K
Exercisable
—
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Direct | Common Stock1.07K shares | 7/17/2026 | M · Option Exercise | −1.07K | 2.48 | — | 84.97K |